These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 2211621)

  • 1. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
    Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
    J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site.
    Hanioka N; Kimura S; Meyer UA; Gonzalez FJ
    Am J Hum Genet; 1990 Dec; 47(6):994-1001. PubMed ID: 1978565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
    Evans WE; Relling MV
    Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
    Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
    Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.
    Evert B; Griese EU; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
    Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
    Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
    Turgeon J; Evans WE; Relling MV; Wilkinson GR; Roden DM
    Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
    Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ
    Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
    Daly AK; Leathart JB; London SJ; Idle JR
    Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.